G1 Therapeutics Inc Stock News

Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

Credit Suisse AG cut its holdings in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) by 11.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,378 shares of the companys stock after selling 2,644 shares during the period. Credit Suisse AGs [] The post Credit Suisse AG Sells 2,644 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) appeared first on ETF Daily News .

Equities research analysts expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to announce sales of $5.58 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for G1 Therapeutics earnings. The highest sales estimate is $6.71 million and the lowest is $5.20 million. G1 Therapeutics posted sales of $16.55 million in the same quarter []

During the last session, G1 Therapeutics Inc. (NASDAQ:GTHX)s traded shares were 0.47 million, with the beta value of the company hitting 2.14. At the end of the trading day, the stocks price was $13.66, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the GTHX share is $37.07, that puts it down G1 Therapeutics Inc. (NASDAQ: GTHX) Received An -38.55% Loss In 6 Months Heres What To Expect Read More »

Brokerages expect that G1 Therapeutics, Inc. (NASDAQ:GTHX) will announce earnings of ($1.03) per share for the current quarter, Zacks reports. Five analysts have made estimates for G1 Therapeutics earnings, with estimates ranging from ($1.10) to ($0.99). G1 Therapeutics posted earnings of ($0.67) per share during the same quarter last year, which indicates a negative year []

G1 Therapeutics is currently facing some pretty severe market penalties, considering they have a drug approved to help in cancer therapy. With several key phase 3 trials ongoing, G1 Therapeutics is po

GTHX had Cosela approved in February for one indication, where there's very little competition. Sales have been as expected, and the company is progressing into other indications.

Analysts predict that G1 Therapeutics, Inc. (NASDAQ:GTHX) will post earnings of ($1.03) per share for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for G1 Therapeutics earnings. The highest EPS estimate is ($0.99) and the lowest is ($1.10). G1 Therapeutics posted earnings per share of ($0.67) during the same quarter last []

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upco

G1 Therapeutics' (GTHX) CEO Jack Bailey on Q3 2021 Results - Earnings Call Transcript

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 2.91% and 12.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Proactive use of trilaciclib prior to chemotherapy in certain patients significantly reduced the use of G-CSFs, ESAs, and RBC transfusions on or after week five of chemotherapy Proactive use of trilac

RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercis